Habits and therapeutic perceptions around HR+/ HER2– metastatic breast cancer in France, based on results from a national survey

摘要

International expert guidelines recommend endocrine treatment with a CDK4/6 inhibitor as first-line treatment for HR+/HER2– advanced breast cancer. However, the levels of evidence and grades of recommendation are weaker for subsequent lines due to the lack of clinical trials evaluating overall therapeutic strategies. Treatment decisions are therefore based on the clinical expertise of the oncologist, which forms a key part of the evidence-based medicine. This observational study aims to describe and measure individual beliefs and habits in the choice of therapeutic strategies.